Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
32.07%
Operating Margin
-18.38%
Net Margin
-22.35%
Efficiency Metrics
Revenue per Expense Ratio
0.84
R&D as % of Revenue
5.54%
Earnings Quality
EBITDA Margin
-8.68%
Income Tax Rate
4,500,000,000.0%
EPS
-10.0600000000
Balance Sheet Analysis
Current Ratio
1.67
Cash Ratio
0.19
Working Capital
$2.54B
Debt to Equity
0.74
Debt to Assets
34.94%
Equity Ratio
47.17%
Cash Flow Analysis
Operating Cash Flow Ratio
-8.47%
Free Cash Flow Ratio
-12.85%
CapEx to Revenue
4.38%
Dividends Paid
$826.00M
Stock Buybacks
No buybacks
Total Shareholder Returns
$826.00M
Cash Position Change
-276.09%
Key Takeaways (2023 FY)
Revenue declined by 7.7250803858521%, indicating potential market challenges
Increased dividend payments by 1.98%
Increased R&D investment by 5.47%
Detailed Growth Metrics
Core Performance
Revenue
-7.73%
Net Income
-39.71%
EPS
-39.72%
Operating Income
-293.58%
Operational Efficiency
R&D Expenses
5.47%
SG&A Expenses
1.07%
Operating Cash Flow
317.10%
Free Cash Flow
681.37%
Balance Sheet Health
Assets
-12.47%
Debt
-1.57%
Book Value per Share
-17.71%
Inventory
-21.39%
Shareholder Returns
Dividends per Share
1.98%
Shares Outstanding
0.00%
Long Term Trends
3Y Revenue/Share
-0.69%
5Y Revenue/Share
-0.91%
3Y Dividend/Share
12.63%
5Y Dividend/Share
23.19%